Radioimmunoassay for pteroylglutamic acid

Area of Science:

• Biochemistry
• Analytical Chemistry
• Clinical Chemistry

Background:

• Folic acid (pteroylglutamate) is essential for numerous metabolic processes.
• Accurate measurement of pteroylglutamate is crucial for diagnosing deficiencies and monitoring treatments.
• Existing methods may lack specificity or sensitivity for various biological matrices.

Purpose of the Study:

• To develop and validate a specific radioimmunoassay for pteroylglutamate determination.
• To assess the assay's performance characteristics, including sensitivity and precision.
• To demonstrate the clinical utility of the assay in absorption studies and during methotrexate therapy.

Main Methods:

• Radioimmunoassay (RIA) utilizing rabbit antiserum raised against a pteroylglutamic acid-methylated bovine serum albumin conjugate.
• Assay validation for specificity, detection limit, and coefficient of variation.
• Application in measuring pteroylglutamate absorption and plasma levels during methotrexate treatment.

Main Results:

• The developed RIA demonstrated a low detection limit of 0.1 microgram/L.
• The coefficient of variation ranged from 4.01% to 14.63%, indicating good precision.
• The assay showed no significant interference from related folates or methotrexate; dihydrofolic acid was measured as pteroylglutamic acid due to oxidation.

Conclusions:

• The radioimmunoassay provides a specific and sensitive method for quantifying pteroylglutamate in plasma, erythrocytes, and urine.
• The assay is clinically applicable for evaluating pteroylglutamate absorption and monitoring folate status in patients undergoing methotrexate therapy.